Answers are grounded in this paper and cite their sources.
Long-term follow-up study demonstrates sustained immune correction in SCID-X1 patients after gene therapy, indicating therapeutic efficacy despite leukemia risks.
After nearly 10 years of follow-up, gene therapy was shown to have corrected the immunodeficiency associated with SCID-X1. Gene therapy may be an option for patients who do not have an HLA-identical donor for hematopoietic stem-cell transplantation and for whom the risks are deemed acceptable. This treatment is associated with a risk of acute leukemia. (Funded by INSERM and others.)
No takes yet. Share an insight, caveat, or question.
Hacein‐Bey‐Abina et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: